China Medical System Holdings Limited

867 KYG211081248

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
6.61 ^HKD	+2.48%		-1.34%	-52.24%

Jun. 25	China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China	CI
Jun. 18	China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China	MT

China Medical System Holdings Limited Renews the Distribution Agreement with BIOCODEX

January 26, 2016 at 09:27 am EST

China Medical System Holdings Limited announced that the group through its wholly-owned subsidiary renewed the distribution agreement with BIOCODEX of France for its product Bioflor on January 25, 2016, with the extended term till December 31, 2021.

Latest news about China Medical System Holdings Limited

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China	Jun. 25	CI
China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China	Jun. 18	MT
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection	Jun. 18	CI
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	May. 09	CI
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	Apr. 23	CI
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
China Medical System Registers New Vitiligo Drug in Macau	Apr. 16	MT
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	Apr. 02	CI
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	Mar. 27	CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	Mar. 19	MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	Mar. 19	CI
China Medical System Obtains Nod For Trials of Two Drugs	Feb. 08	MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	Feb. 07	CI
China Medical Gains License to Sell Kidney Disease Drug Across China	Feb. 05	MT
China Approves Phase 3 Clinical Trial for CMS' Vitiligo Cream	Dec. 13	MT
China Includes CMS' Four Drugs in National Reimbursement List	Dec. 13	MT
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China	Dec. 12	CI
Chinese Regulator Approves China Medical System's Drug Appilcation for Methotrexate Injection	Dec. 05	MT
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China	Dec. 04	CI
Hangzhou HealSun Biopharm Co., Ltd. announced that it has received CNY 200 million in funding from Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited	23-10-06	CI
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	23-09-28	CI

Chart China Medical System Holdings Limited

Duration

Period

Chart China Medical System Holdings Limited

More charts

Company Profile

China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Medical System Holdings Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.138 CNY

Average target price

10.1 CNY

Spread / Average Target

+64.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA MEDICAL SYSTEM HOLDINGS LIMITED	-52.24%	2.07B
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals